| الملخص: | Androgen receptor axis-targeted agents (ARTAs), specifically enzalutamide and
abiraterone acetate, have significantly extended the survival of men with
metastatic castration-resistant prostate cancer (mCRPC), making them the standard
of care for mCRPC. In addition, the impact of both drugs on the health-related
quality of life (HRQoL) represents an important therapeutic objective of mCRPC
patients. This article aimed to review clinical evidence of HRQoL in mCRPC men
treated with abiraterone acetate and enzalutamide and identify their potential
benefits and correlation with overall survival or disease progression based on a
literature search of randomized clinical trials, studies from real clinical
practice and professional guidelines up to October 2022. The synthesized evidence
showed that HRQoL of both novel hormonal therapies (NHTs) was evaluated as a
secondary endpoint in pivotal trials. The results revealed that these novel
agents might improve the HRQoL of mCRPC patients. However, it was difficult to
compare the results between trials due to inconsistencies in trial designs and
instruments. Correlation tests showed a positive correlation with HRQoL and
clinical efficacy outcomes. Patient perspective was assessed only in a few
comparative trials. In conclusion, both abiraterone acetate and enzalutamide
improved the HRQoL of mCRPC patients. Nevertheless, further research is warranted
as there was a limited number of head-to-head trials directly comparing the
overall effects of ARTAs for mCRPC.
|
|---|
